Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
EPS Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+64.2%
5Y CAGR+31.9%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
+64.2%/yr
Quarterly compound
5Y CAGR
+31.9%/yr
Recent acceleration
Percentile
P97
Near historical high
vs 5Y Ago
4x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 229.41% |
| Q3 2025 | 86.51% |
| Q2 2025 | -145.32% |
| Q1 2025 | 300.00% |
| Q4 2024 | 0.71% |
| Q3 2024 | -1.45% |
| Q2 2024 | -35.29% |
| Q1 2024 | 17.74% |
| Q4 2023 | -21.57% |
| Q3 2023 | -6.25% |
| Q2 2023 | -308.70% |
| Q1 2023 | 217.95% |
| Q4 2022 | 51.85% |
| Q3 2022 | -20.90% |
| Q2 2022 | -259.52% |
| Q1 2022 | 170.00% |
| Q4 2021 | 1.64% |
| Q3 2021 | -110.34% |
| Q2 2021 | -11.54% |
| Q1 2021 | -30.00% |
| Q4 2020 | 57.45% |
| Q3 2020 | -261.54% |
| Q2 2020 | 35.00% |
| Q1 2020 | -627.27% |
| Q4 2019 | -122.92% |
| Q3 2019 | -42.86% |
| Q2 2019 | -16.00% |
| Q1 2019 | 92.31% |
| Q4 2018 | 208.33% |
| Q3 2018 | 33.33% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |
| Q4 2017 | -28.57% |
| Q3 2017 | -89.70% |
| Q2 2017 | 8.89% |
| Q1 2017 | 52.35% |
| Q4 2016 | 45.16% |
| Q3 2016 | 3.13% |
| Q2 2016 | 8.57% |
| Q1 2016 | -9.37% |